Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

AstraZeneca is the lead sponsor of 408 current clinical trials in our USA, China, UK, India, Ireland and EU (CTIS) registers. 183 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Durvalumab, Carboplatin and Cisplatin. The most-studied condition is Breast Cancer.

Company profile on this site (news, sites, medicines, approvals): AstraZeneca (GB) →

ClinicalTrials.gov trials by status

Recruiting18348%
Not yet open82%
Active, closed18649%
By invitation10%

Trials by phase

Phase 316443%
Phase 25815%
Phase 15013%
Observational4412%
Phase 1/24311%
Phase 4113%
Not applicable72%
Phase 2/310%

Clinical trials sponsored by AstraZeneca

378 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs NCT05663515 · Pancreatic Cancer	Observational	Recruiting	2024-09	UK
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs NCT07336446 · Prostate Cancer Drug: Saruparib	Phase 1/2	Recruiting	2026-01	UK, USA, China
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis NCT06355934 · ATTR Amyloidosis	Observational	Recruiting	2023-08	UK, USA, China
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases NCT03549754 · Type 2 Diabetes, Hypertension, Chronic Kidney Disease	Observational	Recruiting	2018-02	India
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) NCT07221253 · Biliary Tract Cancer Drugs: Durvalumab, Gemcitabine/Cisplatin, Rilvegostomig	Phase 3	Recruiting	2025-12	UK, USA, India, China
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment NCT07444567 · Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES) Drug: Benralizumab	Phase 3	Recruiting	2026-07	UK, USA, India
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma Drugs: Acalabrutinib, Cyclophosphamide, Doxorubicin	Phase 1/2	Recruiting	2025-01	UK, USA, China
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC NCT07720284 · High-risk Muscle Invasive Urothelial Carcinoma Drugs: Dato-DXd, Durvalumab, Enfortumab Vedotin	Phase 3	Recruiting	2026-07	UK, USA, India, China
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen NCT05624450 · Viral Lung Infection and Acute Respiratory Failure Drug: Tozorakimab	Phase 3	Recruiting	2022-12	UK, USA, India, China
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease NCT06283966 · COPD (Chronic Obstructive Pulmonary Disease)	Phase 3	Recruiting	2024-02	UK, USA, India, China
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) NCT07044336 · Endometrial Cancer, Malignant Solid Tumour Drugs: Adriamycin, Doxorubicin, Paclitaxel	Phase 3	Recruiting	2025-08	UK, USA, China
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations NCT06357533 · Non-Small Cell Lung Cancer Drugs: Dato-DXd, Pembrolizumab, Rilvegostomig	Phase 3	Recruiting	2024-04	UK, USA, India, China
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. NCT07511205 · Healthy Participants, Obesity	Phase 1	Recruiting	2026-03	UK, USA
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) NCT07611110 · Metastatic Castration-resistant Prostate Cancer Drugs: Abiraterone, Apalutamide, Cabazitaxel	Phase 3	Recruiting	2026-05	UK, USA, India, China
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647 · Non-squamous Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Pembrolizumab	Phase 3	Recruiting	2024-11	UK, USA, India, China
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer Drugs: Capecitabine, Ivonescimab, Leucovorin	Phase 3	Recruiting	2026-02	UK, USA, India, China
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT07402915 · Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Drugs: Itraconazole, Torvutatug samrotecan	Phase 1	Recruiting	2026-01	Ireland
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06417814 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Dato-DXd	Phase 3	Recruiting	2024-10	UK, USA, India, China
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients NCT06549595 · ClinicalTrials.gov ↗ · Untreated Follicular Lymphoma Drugs: R-Chop, Surovatamig	Phase 3	Recruiting	2024-08	UK, USA, India, China
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin NCT07662135 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease Drug: Elecoglipron	Phase 3	Recruiting	2026-07	UK, USA, India, China
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab NCT07024706 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Drugs: Acalabrutinib, Venetoclax	Phase 2	Recruiting	2026-06	Ireland, USA
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer NCT06879041 · Metastatic Castration-Resistant Prostate Cancer Drug: AZD2287	Phase 1	Recruiting	2025-03	USA
The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management NCT06909773 · ClinicalTrials.gov ↗ · Cardiovascular Diseases	Not applicable	Recruiting	2025-11	China
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. NCT07215702 · Sepsis, Acute Kidney Injury Drug: AZD4144	Phase 2	Recruiting	2026-02	UK, USA
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT06350097 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Dato-DXd, Osimertinib	Phase 3	Recruiting	2024-04	USA, India, China
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer NCT07218809 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer Drugs: MIRV, Mirvetuximab Soravtansine, Paclitaxel	Phase 3	Recruiting	2025-12	Ireland, UK, USA, India, China
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small Cell Lung Drugs: Pembrolizumab, Rilvegostomig	Phase 3	Recruiting	2025-04	Ireland, UK, USA, China
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids NCT06932263 · ClinicalTrials.gov ↗ · Asthma Drug: Tozorakimab	Phase 2	Recruiting	2025-03	USA, India, China
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) NCT07624305 · ClinicalTrials.gov ↗ · Renal Insufficiency, Chronic Drugs: Balcinrenone/dapagliflozin, Dapagliflozin	Phase 3	Recruiting	2026-09	UK, USA, India
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) NCT06103864 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Carboplatin, Dato-DXd, Durvalumab	Phase 3	Recruiting	2023-11	UK, USA, India, China
AZD5305 hADME in Patients With Advanced Solid Malignancies NCT06713369 · Locally Advanced or Metastatic Solid Tumor Drug: Saruparib	Phase 1	Recruiting	2025-04	UK
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250 · B-cell Malignancies Drug: AZD5492	Phase 1/2	Recruiting	2024-09	USA, China
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment NCT06750289 · ClinicalTrials.gov ↗ · Eosinophilic Asthma	Phase 3	Recruiting	2025-03	Ireland, UK, USA, China
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies NCT05417594 · Advanced Solid Malignancies Drugs: Dato-DXd, Palacaparib, Temozolomide	Phase 1/2	Recruiting	2022-06	UK, USA
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer NCT07181161 · Metastatic Prostate Cancer Drug: Palacaparib	Phase 1/2	Recruiting	2025-10	UK, USA, China
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF NCT07761117 · ClinicalTrials.gov ↗ · Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) Drug: Elecoglipron	Phase 3	Recruiting	2026-08	UK, USA, India, China
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization NCT07088926 · Bronchiectasis With Pseudomonas Aeruginosa Colonization Drug: AZD0292	Phase 2	Recruiting	2025-11	UK, USA
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors NCT05797168 · Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer Drugs: Bevacizumab, Carboplatin, Palacaparib	Phase 1/2	Recruiting	2023-06	UK, USA, China
A Study of AZD0120 in Autoimmune Diseases NCT07295847 · Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis Drug: AZD0120	Phase 1	Recruiting	2026-01	UK, USA
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin NCT07664553 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus Drug: Elecoglipron	Phase 3	Recruiting	2026-07	USA, India, China
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure NCT06742723 · ClinicalTrials.gov ↗ · Chronic Kidney Disease and Hypertension Drug: Baxdrostat/dapagliflozin	Phase 3	Recruiting	2025-03	UK, USA, India, China
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM NCT07667803 · ClinicalTrials.gov ↗ · Weight Management Drug: Elecoglipron	Phase 3	Recruiting	2026-06	UK, USA, India, China
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event NCT07000357 · ClinicalTrials.gov ↗ · Cardiovascular Disease Drug: AZD0780	Phase 3	Recruiting	2025-06	UK, USA, India, China
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Drugs: Capecitabine, Cisplatin, Ivonescimab	Phase 3	Recruiting	2025-03	UK, USA, India, China
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer NCT05061550 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: AZD0171, Carboplatin, Carboplatin, paclitaxel	Phase 2	Recruiting	2022-04	Ireland, USA
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma NCT06921785 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Atezolizumab, Bevacizumab, Rilvegostomig	Phase 3	Recruiting	2025-05	UK, USA, India, China
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) NCT06749457 · Staphylococcus Aureus	Phase 1/2	Recruiting	2024-12	USA
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease NCT07082738 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease (COPD)	Phase 2	Recruiting	2025-06	UK, USA, India, China
Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants NCT07685600 · Healthy Drugs: AZD4144, Itraconazole	Phase 1	Recruiting	2026-07	UK
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. NCT07753993 · ClinicalTrials.gov ↗ · Chronic Kidney Disease Drug: Elecoglipron	Phase 3	Recruiting	2026-08	UK, USA, India, China
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia NCT06137118 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia (B-ALL) Drug: Surovatamig	Phase 1/2	Recruiting	2023-12	UK, USA, China
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drugs: Cisplatin, Durvalumab, Gemcitabine	Phase 3	Recruiting	2024-08	UK, USA, India, China
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC NCT07413757 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Observational	Recruiting	2026-03	China
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin NCT06677060 · ClinicalTrials.gov ↗ · Heart Failure	Phase 3	Recruiting	2025-03	UK, USA, India, China
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours NCT07446855 · ClinicalTrials.gov ↗ · Solid Tumours Drug: Saruparib	Phase 1/2	Recruiting	2026-03	UK, USA
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight NCT07784270 · ClinicalTrials.gov ↗ · Obesity or Overweight, Diabetes Mellitus, Type 2 Drug: AZD6234	Phase 3	Recruiting	2026-08	UK, USA, India, China
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia NCT03813407 · ClinicalTrials.gov ↗ · Hyperkalaemia Drug: Pumitamig	Phase 3	Recruiting	2019-04	UK, USA, India, China
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis NCT07276581 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis	Phase 2	Recruiting	2025-12	UK, USA, China
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations NCT07291037 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC) Drugs: Dato-DXd, Docetaxel	Phase 3	Recruiting	2025-10	UK, USA, India, China
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus NCT07784725 · ClinicalTrials.gov ↗ · Obesity or Overweight Drug: AZD6234	Phase 3	Recruiting	2026-08	USA, India, China
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis NCT07224373 · ClinicalTrials.gov ↗ · Multiple Sclerosis	Phase 1	Recruiting	2025-12	UK, USA
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy NCT05774951 · ClinicalTrials.gov ↗ · Breast Cancer, Early Breast Cancer Drugs: Anastrozole, Camizestrant, Exemestane	Phase 3	Recruiting	2023-03	UK, USA, India, China
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597 · Stomatitis Drug: Dato-DXd	Phase 4	Recruiting	2026-06	USA
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596 · Relapsed or Refractory Multiple Myeloma Drugs: Aldesleukin, Daratumumab	Phase 1/2	Recruiting	2026-07	USA
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer NCT06380751 · ClinicalTrials.gov ↗ · Advanced Breast Cancer Drugs: Abemaciclib, Anastrozole, Camizestrant	Phase 3	Recruiting	2024-08	UK, USA, India, China
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus NCT07662044 · Type 2 Diabetes Mellitus Drugs: Dapagliflozin, Elecoglipron	Phase 3	Recruiting	2026-07	USA, China
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma NCT06106945 · Multiple Myeloma Drugs: Dexamethasone, Elranatamab, Pomalidomide	Phase 1/2	Recruiting	2023-12	USA, China
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy NCT06129864 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Squamous Cell Carcinoma Drug: Volrustomig	Phase 3	Recruiting	2023-12	UK, USA, India, China
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer NCT07205822 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Dato-DXd	Phase 3	Recruiting	2025-10	USA, China
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) NCT06883305 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease (COPD) Drug: Tezepelumab	Phase 3	Recruiting	2025-03	UK, USA, India, China
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma NCT07123454 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin Lymphoma	Phase 1/2	Recruiting	2025-09	UK, USA, China
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism NCT07007793 · ClinicalTrials.gov ↗ · Primary Hyperaldosteronism	Phase 3	Recruiting	2025-08	UK, USA, India, China
Study of Safety and PK of AZD0543 in Healthy Adults NCT07824622 · Human Metapneumovirus Infection	Phase 1	Recruiting	2026-08	USA
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function NCT06307652 · ClinicalTrials.gov ↗ · Heart Failure and Impaired Kidney Function	Phase 3	Recruiting	2024-04	UK, USA, India, China
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus NCT07662109 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus Drugs: Dapagliflozin, Elecoglipron	Phase 3	Recruiting	2026-07	UK, USA, India, China
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC NCT04686305 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Durvalumab	Phase 1	Recruiting	2021-03	USA, China
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation NCT06952803 · ClinicalTrials.gov ↗ · Prostate Cancer Drugs: Abiraterone, Prednisolone/Prednisone, Saruparib	Phase 3	Recruiting	2025-08	UK, USA, India, China
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases NCT06512883 · ClinicalTrials.gov ↗ · Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES) Drug: Benralizumab	Phase 3	Recruiting	2025-04	USA, India
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure NCT06651970 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment Drug: Acalabrutinib	Phase 4	Recruiting	2025-02	UK, USA
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease NCT06531798 · ClinicalTrials.gov ↗ · Moderate to Severe COPD	Phase 4	Recruiting	2026-01	India
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Carboplatin, Nab-paclitaxel, Paclitaxel	Phase 3	Recruiting	2024-11	UK, USA, India, China
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) NCT06079671 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer Drug: Volrustomig	Phase 3	Recruiting	2023-09	USA, India, China
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer NCT07427394 · ClinicalTrials.gov ↗ · Advanced Breast Cancer Drugs: Atirmociclib, Camizestrant	Phase 2	Recruiting	2026-05	UK, USA
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) NCT06455449 · ClinicalTrials.gov ↗ · Polymyositis, Dermatomyositis	Phase 3	Recruiting	2024-06	UK, USA, India, China
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus NCT07662213 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus Drugs: Elecoglipron, Semaglutide	Phase 3	Recruiting	2026-07	UK, USA, China
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies NCT07606066 · ClinicalTrials.gov ↗ · Type 2 Diabetes	Observational	Recruiting	2026-05	USA, India
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL NCT07215585 · ClinicalTrials.gov ↗ · Large B-cell Lymphoma Drug: Surovatamig	Phase 3	Recruiting	2025-11	UK, China
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet) NCT07613424 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Not applicable	Recruiting	2026-06	China
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors NCT06188520 · ClinicalTrials.gov ↗ · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC) Drugs: Abemaciclib, Camizestrant, Palbociclib	Phase 1/2	Recruiting	2023-12	UK, USA
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. NCT06916806 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis Drug: AZD5492	Phase 1	Recruiting	2025-05	UK, USA, China
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) NCT07064122 · ClinicalTrials.gov ↗ · Haematologic Neoplasms	Phase 1	Recruiting	2025-11	UK, USA
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis NCT06465810 · ClinicalTrials.gov ↗ · Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN	Observational	Recruiting	2024-06	UK, USA, China
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants NCT07201558 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis, Systemic Lupus Erythematosus Drug: Surovatamig	Phase 1	Recruiting	2025-12	UK, USA, China
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) NCT05489211 · ClinicalTrials.gov ↗ · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer Drugs: Bevacizumab, Capecitabine, Carboplatin	Phase 2	Recruiting	2022-09	UK, USA, China
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) NCT07509151 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV Drug: Surovatamig	Phase 3	Recruiting	2026-05	UK, USA
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE NCT06897930 · ClinicalTrials.gov ↗ · Lupus Erythematosus, Systemic Drugs: AZD0120, Cyclophosphamide, Fludarabine	Phase 1/2	Recruiting	2025-04	UK, USA
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · ClinicalTrials.gov ↗ · Endometrial Cancer Drugs: Carboplatin, Docetaxel, Paclitaxel	Phase 3	Recruiting	2025-03	UK, USA, China
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies NCT05123482 · ClinicalTrials.gov ↗ · Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer Drugs: Palacaparib, Rilvegostomig, Saruparib	Phase 1/2	Recruiting	2021-10	UK, USA, China
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom NCT05557695 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, CLL Drug: Acalabrutinib	Observational	Recruiting	2022-10	UK
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma NCT06471257 · ClinicalTrials.gov ↗ · Asthma	Phase 3	Recruiting	2024-06	China

Showing the 100 most recently updated of 378 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

AstraZeneca in the EU trials register (CTIS)

30 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with AstraZeneca as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab 2024-518858-17-00 · CTIS ↗ · Neoplasms Drugs: Acalabrutinib, Venetoclax	Phase 2	Ongoing	Ireland + 5 more
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04). 2025-525030-57-00 · Neoplasms Drugs: Dato-DXd, Durvalumab, Enfortumab Vedotin	Phase 3	Authorised	Italy, Poland, Spain + 1 more
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus 2025-523295-23-00 · Nutritional and Metabolic Diseases Drug: AZD6234	Phase 3	Authorised	Sweden
A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age with Systemic Lupus Erythematosus. 2025-524578-41-00 · Immune System Diseases Drug: Anifrolumab	Phase 2	Authorised	Belgium, Portugal
A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus 2026-526171-32-00 · Immune System Diseases	Phase 1	Authorised	Poland, Hungary
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5). 2025-524014-29-00 · Neoplasms Drugs: AZD0120, Bortezomib, Daratumumab	Phase 3	Authorised	Poland, Italy, Denmark + 4 more
A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination with Anti-Cancer Agents in Participants with Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours (PARTHENON) 2025-524171-22-00 · Neoplasms Drug: Saruparib	Phase 1	Authorised	Spain
SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients 2025-523444-12-00 · Neoplasms Drugs: Camizestrant, Ribociclib	Phase 3	Authorised	Poland, Spain, France + 2 more
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment 2025-523307-29-00 · Respiratory Tract Diseases Drug: Benralizumab	Phase 3	Authorised	Denmark, Belgium, France + 4 more
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT) 2025-525016-41-00 · Respiratory Tract Diseases	Phase 2	Ongoing	Poland, Hungary, Netherlands + 7 more
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3) 2025-523935-20-00 · Nutritional and Metabolic Diseases Drug: Elecoglipron	Phase 3	Ongoing	Poland, Germany, Bulgaria + 1 more
A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1) 2023-510098-33-01 · Neoplasms Drugs: Bendamustine, Cyclophosphamide, Doxorubicin	Phase 3	Authorised	Denmark
A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF) 2026-526304-79-00 · Cardiovascular Diseases Drug: Elecoglipron	Phase 3	Ongoing	Spain, Hungary, Germany + 11 more
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD) 2025-523994-41-00 · Cardiovascular Diseases Drug: Elecoglipron	Phase 3	Ongoing	Czechia, Italy, Hungary + 11 more
A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). 2025-523908-75-00 · Cardiovascular Diseases Drug: Eplontersen	Phase 2	Authorised	Germany, Italy, Spain + 2 more
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease 2025-524139-38-00 · Immune System Diseases Drug: Surovatamig	Phase 2	Authorised	France, Germany, Italy + 3 more
A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose‑ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) versus Placebo in Participants of 4 to Less than 12 Years of Age with Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF) (FAROS) 2025-524914-26-00 · CTIS ↗ · Respiratory Tract Diseases	Phase 2	Ongoing	Czechia, Poland, Hungary
Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS) 2023-508533-14-00 · CTIS ↗ · Immune System Diseases Drug: Benralizumab	Phase 3	Ongoing	Poland, Netherlands, France
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS) 2025-523599-21-00 · CTIS ↗ · Neoplasms Drugs: Carboplatin, Cisplatin, Infliximab	Phase 2	Authorised	Spain, Germany
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC) 2025-520626-37-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Belgium, Spain, Poland + 2 more
Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER) 2025-523670-17-00 · CTIS ↗ · Immune System Diseases Drug: Anifrolumab	Phase 3	Ongoing	Poland, Germany, Italy + 2 more
A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA) 2025-524843-11-00 · CTIS ↗ · Neoplasms Drugs: Dato-DXd, Infliximab, Mycophenolate Mofetil	Phase 2	Ongoing	France, Italy, Spain
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4) 2025-523285-25-00 · CTIS ↗ · Neoplasms Drugs: AZD0120, Bortezomib, Carfilzomib	Phase 3	Ongoing	Norway, Poland, Spain + 3 more
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) 2024-519786-22-01 · CTIS ↗ · Neoplasms Drugs: Ramucirumab, Rilvegostomig	Phase 1	Authorised	Germany, Spain, France + 4 more
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1) 2024-516698-56-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Spain
A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Baxdrostat on Albuminuria in Participants with Chronic Kidney Disease and High Blood Pressure 2025-522407-23-00 · CTIS ↗ · Cardiovascular Diseases	Phase 2	Ongoing	Spain, Bulgaria
A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid arthritis or systemic lupus erythematosus. 2025-522273-10-00 · CTIS ↗ · Immune System Diseases	Phase 1	Ongoing	Germany, Spain, Belgium
A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA) 2025-522232-13-00 · CTIS ↗ · Not possible to specify Drug: AZD4144	Phase 2	Ongoing	Germany, France, Spain + 6 more
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression 2025-521299-76-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Germany, Italy, Denmark
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01) 2024-518777-34-00 · CTIS ↗ · Neoplasms Drugs: Doxorubicin, Paclitaxel	Phase 3	Ongoing	Italy, Netherlands, Lithuania + 12 more

Drugs in AstraZeneca trials

171 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 131 more in the trial list above.

Conditions in AstraZeneca trials

309 conditions

By trial register

Register	Trials	Recruiting
Clinical trials in USA	298	148
Clinical trials in China	220	113
Clinical trials in UK	195	100
Clinical trials in India	101	47
Clinical trials in Ireland	10	6
EU register (CTIS)	30	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10
Xijing Hospital	9

Sponsors with the most current trials registered for this condition.

Questions about AstraZeneca trials

How many clinical trials does AstraZeneca sponsor?

AstraZeneca is the lead sponsor of 378 current trials on ClinicalTrials.gov in our USA, China, UK, India and Ireland registers, and 30 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are AstraZeneca trials recruiting?

Yes. 183 of its 378 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is AstraZeneca testing?

Its current trials name 171 drugs and biologicals as interventions. The most frequent are Durvalumab (65), Carboplatin (45), Cisplatin (36), Rilvegostomig (32) and Paclitaxel (30). The number in brackets is how many of its trials name each drug.

Does AstraZeneca have clinical trials in Ireland?

Yes. 10 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

AstraZeneca clinical trials